UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

~~SECURITIES~~Form ~~AND EXCHANGE COMMISSION~~ 6-K

~~Washington,~~REPORT ~~D.C.~~OF ~~20549~~FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

~~FORM~~For ~~6-K~~the month of March 2026

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-41923

~~Eupraxia~~EUPRAXIA ~~Pharmaceuticals~~PHARMACEUTICALS ~~Inc~~INC.(Exact name of Registrant as specified in its charter)

N/A(Translation of ~~registrant~~Registrant’s name ~~into English~~)

201-2067 Cadboro Bay ~~Road~~RoadVictoria, British Columbia, Canada V8R 5G4Telephone: (250) 590-3968 (Address and telephone number of registrant’s principal executive office)

~~Victoria,~~Indicate ~~British~~by ~~Columbia,~~check ~~Canada~~mark ~~V8R~~whether ~~5G4~~the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.Form 20-F [ ] Form 40-F [ X ]

Telephone : (250) 590-3968

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit 99.1 ~~Material~~Press ~~Change~~Release ~~Report,~~ dated ~~February~~March 2317, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Eupraxia Pharmaceuticals Inc..
	EUPRAXIA PHARMACEUTICALS INC.
			(Registrant)
Date: March 17, 2026	By:	/s/ Alex Rothwell
Date: March 6, 2026			/s/ Alex Rothwell
		Name: Alex Rothwell
			Alex Rothwell
		Title: Chief Financial Officer
			Chief Financial Officer

Filing Compare · EUPRAXIA PHARMACEUTICALS INC.